63 related articles for article (PubMed ID: 31864778)
1. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
2. Identification of two novel chemical classes of Autotaxin (ATX) inhibitors using Enalos Asclepios KNIME nodes.
Stylianaki EA; Mouchlis VD; Magkrioti C; Papavasileiou KD; Afantitis A; Matralis AN; Aidinis V
Bioorg Med Chem Lett; 2024 May; 103():129690. PubMed ID: 38447786
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.
Federico L; Jeong KJ; Vellano CP; Mills GB
J Lipid Res; 2016 Jan; 57(1):25-35. PubMed ID: 25977291
[TBL] [Abstract][Full Text] [Related]
5. Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin.
Jiang G; Madan D; Prestwich GD
Bioorg Med Chem Lett; 2011 Sep; 21(17):5098-101. PubMed ID: 21489790
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro, and in silico studies of morpholine-based thiosemicarbazones as ectonucleotide pyrophosphatase/phosphodiesterase-1 and -3 inhibitors.
Tasleem M; Pelletier J; Sévigny J; Hussain Z; Khan A; Al-Harrasi A; El-Kott AF; Taslimi P; Negm S; Shafiq Z; Iqbal J
Int J Biol Macromol; 2024 May; 266(Pt 2):131068. PubMed ID: 38531526
[TBL] [Abstract][Full Text] [Related]
7. Mammalian cell expression, purification, crystallization and microcrystal data collection of autotaxin/ENPP2, a secreted mammalian glycoprotein.
Hausmann J; Christodoulou E; Kasiem M; De Marco V; van Meeteren LA; Moolenaar WH; Axford D; Owen RL; Evans G; Perrakis A
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2010 Sep; 66(Pt 9):1130-5. PubMed ID: 20823545
[TBL] [Abstract][Full Text] [Related]
8. Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design.
Jones SB; Pfeifer LA; Bleisch TJ; Beauchamp TJ; Durbin JD; Klimkowski VJ; Hughes NE; Rito CJ; Dao Y; Gruber JM; Bui H; Chambers MG; Chandrasekhar S; Lin C; McCann DJ; Mudra DR; Oskins JL; Swearingen CA; Thirunavukkarasu K; Norman BH
ACS Med Chem Lett; 2016 Sep; 7(9):857-61. PubMed ID: 27660691
[TBL] [Abstract][Full Text] [Related]
9. Recent insights about pyrrolidine core skeletons in pharmacology.
Poyraz S; Döndaş HA; Döndaş NY; Sansano JM
Front Pharmacol; 2023; 14():1239658. PubMed ID: 37745071
[TBL] [Abstract][Full Text] [Related]
10. Green synthesis, structure optimization and biological evalution of Rhopaladins' analog 2-styryl-5-oxopyrrolidine-2- carboxamide RPDPRH on CaSki cells.
Ke LN; Kong LQ; Zhu XL; Wu FX; Chen QH; Li B; Dong Y; Wang HM; Zeng XH
Front Chem; 2022; 10():975559. PubMed ID: 36110131
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of a Novel Class of Autotaxin Inhibitors Based on Endogenous Allosteric Modulators.
Clark JM; Salgado-Polo F; Macdonald SJF; Barrett TN; Perrakis A; Jamieson C
J Med Chem; 2022 Apr; 65(8):6338-6351. PubMed ID: 35440138
[TBL] [Abstract][Full Text] [Related]
12. Design and Development of Autotaxin Inhibitors.
Jia Y; Li Y; Xu XD; Tian Y; Shang H
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832985
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds.
Li Petri G; Raimondi MV; Spanò V; Holl R; Barraja P; Montalbano A
Top Curr Chem (Cham); 2021 Aug; 379(5):34. PubMed ID: 34373963
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
16. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
[TBL] [Abstract][Full Text] [Related]
18. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
